Quarterly results and guidance from the drugmakers that matter.
The US genetic testing company reported third-quarter revenue of $794M and a surge in clinical MRD oncology volumes, and raised its full-year revenue guidance.
ARS Pharmaceuticals posted $37.7M total third-quarter revenue, cut SG&A sharply and said interim Phase 2b data for ARS-2 in chronic spontaneous urticaria flares are due in Q1 2027.
The company has no product revenue yet, as gedatolisib shipments began only on 30 September, while payer coverage is reported at 91% of US commercial and Medicare lives.
The US diagnostics company lifted its full-year outlook to $1.36-1.37 billion as Oncology volumes grew and Shield screening tests rose to 83,000, alongside new FDA companion diagnostic approvals.
The KIT inhibitor faces FDA action dates in GIST, non-advanced and advanced systemic mastocytosis, as Cogent reports $791.1 million in cash for Q3 2026.
The cell therapy maker reported third-quarter net income of $14.2m, raised full-year revenue and adjusted EBITDA margin guidance, and said a possible 2027 UK launch of MACI remains on track.
The US vaccine developer reported $68 million in third-quarter revenue and a $31 million net loss, with cash of $627 million at the end of the period.
Intellia's Q3 2026 update confirms FDA acceptance of its hereditary angioedema CRISPR therapy filing, alongside completed MAGNITUDE-2 enrolment and a new loan of up to $400 million.
Viatris reported third-quarter revenue of $3.75bn and a GAAP net loss, citing a US approval, a Japanese approval and a product launch.
The radiopharmaceutical company reported third-quarter results, cited two FDA approvals and a CMS reimbursement decision, and suspended 2026 guidance because of its pending Curium merger.
The medtech group also reports FDA Breakthrough Device Designation for its Freesolve magnesium scaffold and a completed OEM divestiture, with the Intersurgical sale still awaiting regulatory approval.
Growth in the ADHD portfolio offset an 18% fall in pain products, and the company reaffirmed its 2026 guidance.
The model-informed drug development company narrowed its 2026 revenue growth outlook to 2% to 3% and appointed Grant Peterson as Chief Product Officer.
The US insulation-materials maker booked $15.1 million of incident-related costs and expects restoration of its East Providence facility to finish in the first half of 2027.
The US device maker reaffirmed its 2026 revenue guidance, lowered its operating expense outlook and began a full commercial launch of its AYON power liposuction handpiece.
The agency has pushed back its decision by three months after treating Agios' reply on a possible REMS as a major amendment, as the firm reported Q3 results and R&D cuts.
Akebia reported a $14.4M third-quarter net loss as growth in Vafseo use among dialysis patients failed to offset falling sales of Auryxia.
The US drugmaker now expects LINZESS net sales of $1.20-$1.25bn, while its confirmatory Phase 3 STARS-2 trial of apraglutide in short bowel syndrome continues.
The gene therapy developer plans a pre-BLA meeting in Q4 2026 for its Duchenne candidate, while the FDA hold on its MPS II programme remains in place.
Dyne Therapeutics reports a PDUFA date for its Duchenne muscular dystrophy BLA alongside one-year myotonic dystrophy data, a wider third-quarter loss and a cash runway into Q2 2028.
Entrada Therapeutics says ELEVATE-45-201 Cohort 1 met its safety and tolerability objective, with Cohort 2 data for both Duchenne programmes expected in the first half of 2027.
The US antibody developer says its 2026 data guidance was met, with an ITP update due at ASH in December and further data planned for 2027.
The animal health company reported third-quarter revenue of $2.4B, with US companion animal sales down 8%, and flagged new FDA actions including a screwworm emergency authorisation for Simparica Trio.
BeOne Medicines reported third-quarter revenue of $1.9bn, with BRUKINSA sales of $1.4bn, and lifted its full-year revenue and operating income guidance.
The gene therapy company reported net income of $35.8 million and positive cash flow, with an EMA marketing application for Papzimeos under review.
The US life-sciences supplier reported third-quarter revenue of $45.9 million, with TriLink mRNA products up 28%, and raised its full-year revenue and Adjusted EBITDA outlook.
Clinical Diagnostics growth offset a decline in Life Science, while a fair-value change on the Sartorius holding drove GAAP net income of $458.6 million; full-year guidance is unchanged.
The cancer diagnostics company also bought Convergent Genomics, won Medicare coverage for Prosigna and lowered its full-year testing revenue forecast.